The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi’s sarcoma cells in vitroTonia Luca, Giulia Di Benedetto, Mariagrazia Rita Scuderi, Marco Palumbo,
Silvia Clementi, Renato Bernardini, Giuseppina Cantarella
European Journal of Pharmacology 2009
Kaposi’s sarcoma is a highly vascularized mesenchymal neoplasm arising with multiple lesions of the skin. Endogenous cannabinoids have been shown to inhibit proliferation of a wide spectrum of tumor cells. We studied the effects of cannabinoids on human Kaposi’s sarcoma cell proliferation in vitro. To do so, we first investigated the presence of the cannabinoid receptors CB1 and CB2 mRNAs in the human Kaposi’s sarcoma cell line KS-IMM by RT-PCR and, subsequently, the effects of the mixed CB1/CB2 agonist WIN-55,212-2 (WIN) on cell proliferation in vitro. WIN showed antimitogenic effects on Kaposi’s sarcoma cells. Western blot analysis of Kaposi’s sarcoma lysates suggested that WIN treatment induced activation of both caspase-3 and -6, as well as increased phosphorylation of the stress kinase p38 and JNK, along withtransient phopsphorylation of ERK1/2. To better characterize the involvement of each single CB receptor in cannabinoidinduced cell death, we incubated Kaposi’s sarcoma cells with different selective cannabinoid receptor agonists, respectively ACEA (CB1) and JWH-133 (CB2). None of the agonists was able to induce KS-IMM cell apoptosis. Moreover, we co-incubated Kaposi’s sarcoma cells with WIN-55,212-2 and either the CB1 receptor antagonist AM251, the CB2 receptor antagonist AM630, or a combination of both substances. The CB2 receptor antagonist AM630 was able to significantly increase survival of Kaposi’s sarcoma cells treated with WIN. In view of the antiproliferative effects of cannabinoids on KS-IMM cells, one could envision the cannabinoid system as a potential target for pharmacological treatment of Kaposi’s sarcoma.
Source: The CB1/CB2 Receptor Agonist WIN-55,212-2 Reduces Viability Of Kaposi’s Sarcoma Cells